Physician profile
Jessica Mcabee Coleman
NPI 1376785394
$929,635.82
in general payments reported to CMS, 2019-2025
35 companies · $267K in 2025
The $267K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $33K · 2021: $78K · 2022: $143K · 2023: $155K · 2024: $194K · 2025: $267K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $207K · Travel and Lodging: $142K · Consulting Fee: $107K · Honoraria: $94K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $43K · Food and Beverage: $21K · Education: $526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $207,489.50 |
| Travel and Lodging | $142,343.83 |
| Consulting Fee | $107,250.31 |
| Honoraria | $94,348.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $42,700.00 |
| Food and Beverage | $20,919.12 |
| Education | $525.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $202,540.30 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Travere Therapeutics, INC. | $186,141.37 | 2022-2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $115,926.48 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $73,002.32 | 2022-2025 | Purified Cortrophin Gel |
| Akebia Therapeutics INC | $51,789.92 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $51,262.75 | 2019-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $39,435.19 | 2021-2024 | Jesduvroq, Benlysta |
| Otsuka America Pharmaceutical, INC. | $39,230.10 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $38,001.50 | 2022-2025 | Tarpeyo |
| Amgen INC. | $37,818.86 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Fresenius USA Marketing, INC. | $34,483.07 | 2019-2025 | Korsuva, Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $22,358.01 | 2024-2025 | |
| Ardelyx, INC. | $18,585.93 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Horizon Therapeutics Plc | $11,930.15 | 2021-2023 | Krystexxa |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,791.67 | 2022-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,578.57 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $1,315.00 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $1,034.44 | 2020-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $265.74 | 2021-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $190.77 | 2019-2024 | Rayaldee |
| Nxstage Medical, INC. | $178.79 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $159.31 | 2019 | |
| Corcept Therapeutics | $146.98 | 2023-2025 | Korlym |
| One Lambda, INC. | $128.29 | 2025 | |
| Alexion Pharmaceuticals, INC. | $72.73 | 2019-2023 | Strensiq |
| Chiesi USA, INC. | $52.15 | 2024-2025 | Elfabrio |
| Daiichi Sankyo INC. | $34.78 | 2019-2021 | |
| Kyowa Kirin, INC. | $28.50 | 2025 | |
| Apellis Pharmaceuticals, INC. | $23.68 | 2025 | |
| Novo Nordisk INC | $23.49 | 2025 | Ozempic |
| Abbott Laboratories | $23.14 | 2025 | Freestyle Libre |
| Inspire Medical Systems, INC. | $21.80 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.12 | 2023 | Jardiance |
| Shield Therapeutics INC | $20.69 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.